High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial)

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.

Elevated hydrogen sulfide (H2S) contributes to vasodilatation and hypotension in septic shock, and traditional therapies do not target this pathophysiologic mechanism.

ClinicalTrials.gov; No.: NCT03783091; URL: www.

Who Took Part

PubMed indexes the participants as adults.

The primary outcome was study feasibility (enrollment rate, clinical and laboratory compliance rate, and contamination rate).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled, parallel-group and pilot study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Cyanocobalamin (Vitamin B12), so expectations could not easily colour the readings.

Some participants received a placebo instead of Cyanocobalamin (Vitamin B12), giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

PubMed files the paper under topics including Shock, Septic, Hydroxocobalamin, Pilot Projects, Vitamin B 12, Vasoconstrictor Agents and Hypotension.

Author keywords: ICU, critical care, feasibility, hydrogen sulfide, outcomes and sepsis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Chest), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page.